Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Anticholinergic burden and sedative medicines
Medicine of older adults · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Severe sedative or anticholinergic toxicity
Airway obstruction, respiratory depression, coma, seizure, hyperthermia, arrhythmia, severe agitation, urinary retention or ileus may follow overdose, interaction or accumulation and can deteriorate rapidly.
Action: Use ABCDE and glucose, monitor ECG and temperature, support airway and ventilation, stop further exposure, check renal and hepatic function and obtain poisons advice; use naloxone for suspected opioid toxicity according to the emergency protocol.
Overview
Recognise cumulative anticholinergic and sedative toxicity, distinguish drug effects from acute disease, and reduce exposure safely while protecting the clinical indications, withdrawal risks and functional priorities of older adults.
Map the phenotype and timeline. Ask attention, memory, hallucinations, sleepiness, falls, dry mouth, swallowing, blurred vision, bowel frequency, urinary stream and retention. Establish the stable cognitive and functional baseline from collateral. A new medicine, dose increase, renal decline or acute infection often precedes deterioration, but a temporal association does not exclude stroke, sepsis or other emergencies.
Reconcile exposure by ingredient and pharmacological effect. Include over-the-counter sleep aids and antihistamines, tricyclics used for pain, bladder antimuscarinics, antiemetics, antipsychotics, opioids, benzodiazepines, Z-drugs, gabapentinoids, muscle relaxants and alcohol. Note timing: several night medicines can still impair morning transfers and driving.
Examine arousal, attention, pupils, mouth, temperature, pulse, blood pressure including standing measurements, bladder, abdomen, gait and focal neurology. Use 4AT when delirium is possible. Check capillary glucose and pursue infection, hypoxia, pain, retention, constipation, dehydration, head injury and metabolic causes according to findings. Treat these contributors in parallel rather than diagnosing burden by a score.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Medicine of older adultsOriginal SBA
Interpreting an anticholinergic score
An 83-year-old with delirium and urinary retention takes several medicines with anticholinergic properties. How should a burden score be used?
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Anticholinergic scales classify drugs differently and do not account perfectly for dose, blood-brain penetration, renal clearance or individual sensitivity. Use a recognised scale consistently as a conversation prompt, then verify each medicine's actual indication and effect. A low score does not make a sedative combination safe, and a high score does not mandate abrupt withdrawal.
Prioritise immediate danger. Marked sedation or respiratory depression requires airway support, monitoring and opioid toxicity management where appropriate. Retention needs bladder assessment and relief; ileus requires urgent evaluation. Delirium care includes orientation, sensory aids, hydration, sleep, bowel and bladder treatment, movement and medication review.
For ongoing optimisation, identify the medicine contributing most harm with the least current benefit. Consider non-anticholinergic bladder strategies, non-drug sleep treatment, psychological treatment, pain rehabilitation and environmental approaches to distress. For dementia-related behaviour, investigate pain, infection, communication, environment and unmet need before antipsychotic exposure and review any continued prescription frequently.
Reduce dependence-forming or psychotropic treatment through a shared taper. Explain likely withdrawal and relapse, choose a pace based on dose, duration and previous attempts, and make smaller reductions where needed. Avoid compensating for withdrawal insomnia or anxiety by adding another sedative. Involve psychiatry, pain, neurology or palliative care when the indication or risk requires expertise.
Renal and hepatic function materially alter choices. Morphine and several gabapentinoids can accumulate with kidney impairment; active metabolites and long half-lives prolong sedation. Low albumin, low weight and acute inflammation also affect exposure. Use current product and BNF dosing and repeat assessment after dehydration or acute kidney injury.
Functional mitigation matters during change. Schedule supervised mobility when alert, provide the correct aid and lighting, plan toileting, prevent constipation, make fluids accessible and restore glasses and hearing aids. Review driving and hazardous tasks while daytime impairment persists. Carers need clear signs of excessive sedation, withdrawal and when to seek urgent help.
Measure outcomes meaningful to the person: time awake, clarity, sleep quality, pain, continence, bowel function, falls and independence. If cognition does not improve, reopen the diagnosis rather than restarting automatically. Update all records and dispensing systems after a stop, and retain the rationale and response for future clinicians.
Key points
Anticholinergic burden is cumulative exposure to medicines with antimuscarinic effects; sedative burden similarly reflects combined CNS-depressant effects.
Suspect harm when delirium, memory decline, dry mouth, blurred vision, constipation, retention, falls or daytime sleepiness follows a drug change.
First-line assessment reconciles every prescribed and purchased product, alcohol, dose, timing, indication, renal function and recent addition or escalation.
Burden scores can prompt review but differ by scale and do not prove causality or replace examination and acute-illness assessment.
High-yield classes include bladder antimuscarinics, tricyclic antidepressants, sedating antihistamines, antipsychotics, opioids, benzodiazepines, Z-drugs and gabapentinoids.
Opioid plus benzodiazepine exposure can cause fatal respiratory depression; prescribe together only when alternatives are inadequate and monitor closely.
First reduce the medicine with weakest indication or greatest harm, while treating pain, sleep, mood, bladder or behavioural needs through safer alternatives.
Do not abruptly stop long-term benzodiazepines, Z-drugs, opioids, gabapentinoids, antidepressants or antipsychotics; use an individual supported taper.
Aetiology
01
Multiple anticholinergic medicines
Bladder antimuscarinics, tricyclics, sedating antihistamines, antipsychotics and other agents contribute overlapping muscarinic blockade across several organ systems.
02
CNS depressant combinations
Opioids, benzodiazepines, Z-drugs, gabapentinoids, antipsychotics and alcohol add sedation, respiratory depression and impaired coordination during ordinary tasks.
03
Reduced clearance and sensitivity
Frailty, low body mass, kidney or liver impairment and acute illness increase exposure and central nervous system response.
04
Prescribing cascades
Drug-induced constipation, retention, dizziness or sleep disruption is treated as separate disease, expanding burden without removing the cause.
Pathophysiology
1
Central cholinergic blockade
Reduced acetylcholine signalling impairs attention, memory and arousal, with greater clinical effect in dementia and delirium vulnerability.
2
Peripheral muscarinic blockade
Reduced salivation, accommodation, gut motility and bladder contraction causes dry mouth, blurred vision, constipation and retention.
3
Additive neural depression
Different receptor mechanisms converge on reduced vigilance, postural responses and respiratory drive, making combined exposure more dangerous.
4
Functional amplification
Sedation, blurred vision and posture change interact with frailty, mobility aids and nocturia to convert small pharmacological effects into falls.
5
Adaptation and withdrawal
Long-term receptor adaptation means abrupt reduction of sedatives or psychotropics can produce rebound insomnia, anxiety, agitation or seizures.
Find accumulation, metabolic trigger and rhythm harm.
Interpretation and limitations
Use glucose, renal, electrolytes, liver, blood gases, ECG and concentrations according to phenotype and specific exposure.
05Anticholinergic burden tool
Why
Structure identification of cumulative exposure.
Interpretation and limitations
Differential diagnosis
01
Delirium from acute illness
Infection, hypoxia, pain, retention, constipation and metabolic disturbance often coexist and require active investigation despite a risky medicine list.
02
Dementia progression
Gradual cognitive decline differs from abrupt fluctuation, but high burden can worsen function and obscure the true baseline.
03
Depression or sleep disorder
Daytime slowing and poor concentration may reflect mood, sleep apnoea or circadian disruption rather than drug effect alone.
04
Neurological or vestibular disease
Stroke, Parkinsonism, neuropathy and vestibular disorders produce falls and cognitive symptoms requiring localisation and directed testing.
Management
01First-line burden reviewFind the effects that matterFirst stepFirst lineCognitive, bowel, bladder, sleep or mobility change may be medicine-related.+
1Reconcile all exposures and establish symptom timing, cognitive baseline, organ function and the indication for each contributor.
2Exclude and treat acute illness, retention, loading, hypoxia, pain and neurological danger while using burden tools only as prompts.
3Prioritise the weakest-benefit, highest-harm exposure and agree a supported reduction or substitution with outcome measures.
02Respiratory toxicity routeReverse life-threatening CNS depressionBreathing or consciousness is impaired during opioid or sedative exposure.+
1Provide airway and ventilatory support, glucose, monitoring and urgent assessment of exact drugs, dose, timing and renal function.
Complications
01
Delirium and cognitive impairment
Cumulative central effects precipitate fluctuating attention, distress, immobility and prolonged hospital or care needs after the acute trigger resolves.
02
Falls and fracture
Reduced alertness, reaction speed, vision and posture increases injury risk, especially during night-time toileting or unfamiliar transfers.
03
Respiratory depression
Opioid and sedative combinations can suppress breathing, with particular danger in sleep apnoea, chest disease and frailty.
04
Retention, ileus and aspiration
Peripheral blockade and depressed consciousness can cause urinary obstruction, faecal loading, vomiting and unsafe swallowing with secondary infection.
05
Withdrawal and rebound
Unplanned cessation may provoke seizures, autonomic symptoms, severe insomnia, anxiety, pain escalation or psychiatric relapse requiring urgent reassessment.
Monitoring and follow-up
Record respiratory rate and arousal closely during acute toxicity and after any naloxone because opioid effect may recur.
Follow attention, daytime alertness and the stable cognitive baseline after staged reductions.
Track falls, near-falls, lying-standing pressure, gait and night-time toileting exposure.
Review bowel frequency, urinary emptying, dry mouth, swallowing and nutrition as antimuscarinic effects change.
Monitor withdrawal and return of the treated condition using a pre-agreed symptom measure.
Repeat renal and hepatic safety review after acute illness, dehydration or substantial weight change.
Confirm discontinued items are removed from repeats, dispensing and care-administration records.
Special situations
Scales disagree
A burden score depends on its drug list and cannot replace dose, indication and individual response.
Peripheral clues support the history
Dry mouth, retention and constipation can make a central medicine contribution more plausible.
Several small effects combine
Modest posture, vision and alertness changes can together make the toilet route unsafe.
Kidney injury changes yesterday's dose
A stable prescription becomes toxic when clearance falls, even without an intentional dose change.
Alertness needs rehabilitation
Removing sedation does not automatically reverse the strength and confidence lost during immobility.
Common pitfalls
01
Diagnosing drug toxicity without checking glucose, infection, retention and focal neurology.
02
Treating an anticholinergic score as a diagnostic or mandatory stop threshold.
03
Adding a laxative or catheter while leaving an avoidable causal medicine unreviewed.
04
Combining opioids and benzodiazepines without documenting necessity and monitoring.
05
Stopping long-term sedatives abruptly after a fall.
06
Assuming a prescribed drug cannot impair driving or breathing.
07
Failing to reassess function after cognitive and sedative burden improves.
Protect hydration, bowel and bladder function, vision, hearing, mobility and night-time toileting while medicine changes take effect.
Review actual alertness, cognition, falls and function after change, and communicate discontinued drugs so outdated lists do not restart them.
New focal deficit, meningism, hypoglycaemia, sepsis or head injury must not be mislabelled as medication-related confusion.
Fall with head strike or inability to weight bear during sedative treatment requires parallel trauma assessment.
Abrupt cessation after long exposure can cause seizure, delirium, autonomic instability or severe psychological withdrawal.
Renal decline, dehydration or addition of another CNS depressant can convert a stable dose into acute accumulation.
Use one recognised scale as an aid, recognising inter-scale disagreement, dose limitations and incomplete sedative coverage.
06Functional and environmental assessment
Why
Quantify real-world medicine harm and dependency.
Interpretation and limitations
Observe transfers, gait, toileting, eating, swallowing and medication administration with usual aids and support.
2
Use naloxone for suspected opioid toxicity under the emergency protocol and seek poisons or critical-care advice for mixed exposure.
3After stabilisation, redesign analgesia and sedative treatment, provide overdose education and arrange early review.
03Supported taper routeReduce without provoking withdrawalA long-term sedative or psychotropic drug contributes to burden.+
1Explain the likely benefit, withdrawal risks and alternatives and agree an individual pace and monitoring plan.
2Reduce stepwise with smaller changes when needed, pausing or returning to the last tolerated dose for severe symptoms.
3Treat the original pain, insomnia, anxiety or distress and document outcomes and future restart criteria.
04Functional recovery routeConvert alertness into independenceToxicity has reduced mobility, eating or self-care.+
1Restore hydration, bowel and bladder function, sensory aids, nutrition and safe day-night routines.
2Use physiotherapy and occupational therapy to reassess gait, transfers, equipment and home hazards as alertness improves.
3Review care input and medicine self-administration rather than assuming previous dependency is permanent.